Skip to main content
Log in

Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

We compared 3'[F-18]fluoro-3'-deoxythymidine (FLT) positron emission tomography (PET) and 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) for PET visualization of head and neck squamous cell cancers (HNSCCs) and evaluated which might better reflect proliferative activity as indicated by the Ki-67 index.

Procedures

A total of 43 patients with HNSCCs were examined with FLT-PET and FDG-PET. The PET images were evaluated qualitatively for regions of focally increased metabolism and for semiquantitative analysis the maximum standardized uptake value (SUV) was calculated.

Results

For depiction of primary tumours, the sensitivity of both approaches was 100%. The mean (±SD) SUV for FLT (5.65 ± 2.96) was significantly lower than that for FDG (10.9 ± 4.91; p < 0.0001). No significant differences were found for the T category. However, the mean (±SD) FLT SUV was significantly higher in poorly than in well-differentiated tumours (6.49 ± 3.13 vs. 4.2 ± 2.08; p < 0.04). Similarly, FDG SUVs in poorly and moderately differentiated tumours (12.72 ± 4.8 and 11.46 ± 4.64) were significantly higher than in well-differentiated tumours (7.45 ± 3.51; p < 0.004 and p < 0.02). No significant correlation was observed with the Ki-67 index for either.

Conclusion

FLT-PET showed as high a sensitivity as FDG-PET for the detection of primary HNSCC lesions, although uptake of FLT was significantly lower than that of FDG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332

    Article  PubMed  Google Scholar 

  2. Laubenbacher C, Saumweber D, Wagner-Manslau C et al (1995) Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 36:1747–1757

    CAS  PubMed  Google Scholar 

  3. Klabbers BM, Lammertsma AA, Slotman BJ (2003) The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol 5:257–270

    Article  PubMed  Google Scholar 

  4. Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942–946

    Article  CAS  PubMed  Google Scholar 

  5. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eue J Nucl Med 2:1409–1415

    Article  Google Scholar 

  6. Kubota K (2001) From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15:471–486

    Article  CAS  PubMed  Google Scholar 

  7. Ac B, Schirrmeister HH, Guhlmann CA et al (2001) Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 42:721–725

    Google Scholar 

  8. Shields AF, Larson SM, Grunbaum Z, Graham MM (1984) Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med 25:759–764

    CAS  PubMed  Google Scholar 

  9. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JC (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210–1217

    CAS  PubMed  Google Scholar 

  10. Francis DL, Freeman A, Visvikis D et al (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52:1602–1606

    Article  CAS  PubMed  Google Scholar 

  11. van Westreenen H, Cobben DCP, Jager PL et al (2005) Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 46:400–404

    PubMed  Google Scholar 

  12. Smyczek-Gargya B, Fersis N, Dittmann H et al (2004) PET with [18F] fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31:720–724

    Article  PubMed  Google Scholar 

  13. Yamamoto Y, Nishiyama Y, Ishikawa S et al (2007) Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34:1610–1616

    Article  CAS  PubMed  Google Scholar 

  14. Cobben DC, Van der Laan BF, Maas B et al (2004) 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med 45:226–231

    PubMed  Google Scholar 

  15. Linecker A, Kermer C, Sulzbacher I et al (2008) Uptake of 18F-FLT and 18F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 47:80–85

    CAS  PubMed  Google Scholar 

  16. Sobin LH, Wittekind Ch (eds) (1997) UICC: TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York

    Google Scholar 

  17. Machulla HJ, Blocher A, Kuntzsch M, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Ch 24:843–846

    Article  Google Scholar 

  18. Minn H, Lapela M, Klemi PJ et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911

    CAS  PubMed  Google Scholar 

  19. Slevin NJ, Collins CD, Hastings DL et al (1999) The diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer. J Laryngol Otol 113:548–554

    Article  CAS  PubMed  Google Scholar 

  20. Kameyama R, Yamamoto Y, Izuishi K et al (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36:382–388

    Article  PubMed  Google Scholar 

  21. Barthel H, Cleij MC, Collingridge DR et al (2003) 3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791–3798

    CAS  PubMed  Google Scholar 

  22. Apisarnthanarax S, Alauddin MM, Mourtada F et al (2006) Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12:4590–4597

    Article  CAS  PubMed  Google Scholar 

  23. Troost EG, Vogel WV, Merkx MA et al (2007) 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48:726–735

    Article  PubMed  Google Scholar 

  24. Pio BS, Park CK, Pietras R et al (2006) Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8:36–42

    Article  PubMed  Google Scholar 

  25. Herrmann K, Wieder HA, Buck AK et al (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Clin Cancer Res 13:3552–3558

    Article  CAS  Google Scholar 

  26. Yang YJ, Ryu JS, Kim SY et al (2006) Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33:412–419

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroshi Hoshikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoshikawa, H., Nishiyama, Y., Kishino, T. et al. Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers. Mol Imaging Biol 13, 172–177 (2011). https://doi.org/10.1007/s11307-010-0331-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-010-0331-z

Key words

Navigation